Bamco Inc. NY Has $661,000 Stake in Genmab A/S (NASDAQ:GMAB)

Bamco Inc. NY cut its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 56.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,691 shares of the company's stock after selling 40,683 shares during the quarter. Bamco Inc. NY's holdings in Genmab A/S were worth $661,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the company. Brandywine Global Investment Management LLC purchased a new position in shares of Genmab A/S during the fourth quarter worth about $33,804,000. Marshall Wace LLP raised its holdings in shares of Genmab A/S by 162.2% during the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock valued at $23,422,000 after buying an additional 694,243 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Genmab A/S by 18,959.1% in the fourth quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company's stock worth $10,660,000 after acquiring an additional 508,104 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Genmab A/S by 3,049.3% in the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock valued at $8,507,000 after buying an additional 394,670 shares during the last quarter. Finally, Trexquant Investment LP raised its stake in Genmab A/S by 495.1% during the fourth quarter. Trexquant Investment LP now owns 379,936 shares of the company's stock worth $7,929,000 after acquiring an additional 316,089 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on GMAB. Truist Financial lowered their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Genmab A/S presently has an average rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Stock Down 0.2 %

Shares of GMAB traded down $0.03 during mid-day trading on Friday, reaching $19.39. The company's stock had a trading volume of 2,185,465 shares, compared to its average volume of 1,086,414. The company has a market cap of $12.43 billion, a price-to-earnings ratio of 11.14, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04. The business has a fifty day moving average of $20.15 and a 200 day moving average of $20.91. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.05. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.